CD40LG and systemic lupus erythematosus: Second, the present data, together with those of previous studies, are unable to rule out the possibility that all findings were unique to IgM or to claim that the number rather than the type of immunoreactants was a more predictable factor in evaluating SLE activity because the group of patients with one immunoreactant mainly comprised IgM-alone patients.